Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening

S Chatfield, G Owen, H C Ryley, J Williams, M Alfaham, M C Goodchild, P Weller

Abstract
Screening for cystic fibrosis by measurement of immunoreactive trypsin in the blood has now been done for 10 years, since Crossley et al first described the phenomenon of raised immunoreactive trypsin values in heel-prick blood samples from neonates with cystic fibrosis.1 2 Reasons for screening for cystic fibrosis (or any other disease) rest upon the principles of Wilson and Jungner.3 In essence, the disease should have a latent or early symptomatic state that can be modified by agreed treatment. While the former is usually true for cystic fibrosis, there is at present no agreed treatment protocol.4 Several groups have attempted to substantiate the case for screening for cystic fibrosis by making longitudinal comparisons of screened patients and those recognised in previous years by clinical criteria.5-8 Other reports have concerned the better clinical state of children with cystic fibrosis who were diagnosed during the first year of life—earlier than contemporaries9 or siblings.10 All these studies have been open to the criticism that like has not been compared with like.11 The diagnostic delay that occurs in cystic fibrosis can, however, be improved by screening,12 and the identification of nutritional deficiencies by screening in some infants with cystic fibrosis before the age of 2 months gives further support for screening and early diagnosis.13
To find out the possible clinical benefits of early diagnosis after screening, a large comparative study of screening for cystic fibrosis by measurement of immunoreactive trypsin on routinely collected blood spots (Guthrie card specimens 5–10 days of age) was set up in Wales and the West Midlands in January 1985, funded by the Cystic Fibrosis Research Trust. During the five year period 227 183 neonates were screened for cystic fibrosis (table 1) and an estimated 246 959 were not screened (table 2). In this paper we make a clinical comparison between screened and clinically diagnosed patients from data produced to December 1989.

Patients and methods
IDENTIFICATION OF PATIENTS
The protocol of the trial has been described previously.11 Infants born in Wales (population 2-7 million) and the West Midlands (population 4-1 million) were tested on alternate weeks, thus identifying two groups in each area: screened and unscreened. Results for patients in both areas are considered together.
Specimens from neonates collected in central Birmingham were sent to a separate local screening laboratory and no children born in the central Birmingham area are included in this study.

Table 1 Details of infants screened 1985–9. Total number of specimens received: 227 183

<table>
<thead>
<tr>
<th>Specification</th>
<th>No of specimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive first immunoreactive trypsin test</td>
<td>947 (44.2%)</td>
</tr>
<tr>
<td>Positive second immunoreactive trypsin test</td>
<td>98</td>
</tr>
<tr>
<td>False positive tests (sweat test negative)</td>
<td>33</td>
</tr>
<tr>
<td>Infants identified as having cystic fibrosis</td>
<td>65</td>
</tr>
<tr>
<td>(sweat test positive)</td>
<td></td>
</tr>
<tr>
<td>Not at risk</td>
<td>58</td>
</tr>
<tr>
<td>With meconium ileus</td>
<td></td>
</tr>
<tr>
<td>With elder sibling with cystic fibrosis</td>
<td>4</td>
</tr>
<tr>
<td>Specimens giving false negative diagnoses for cystic fibrosis</td>
<td>13</td>
</tr>
<tr>
<td>Not at risk</td>
<td>9</td>
</tr>
<tr>
<td>With meconium ileus</td>
<td>3</td>
</tr>
<tr>
<td>With elder sibling with cystic fibrosis</td>
<td>1</td>
</tr>
<tr>
<td>Total No of cases of cystic fibrosis diagnosed by screening</td>
<td>78 (1/2912)</td>
</tr>
</tbody>
</table>

Table 2 Details of infants who were not screened 1985–9

<table>
<thead>
<tr>
<th>Specification</th>
<th>No of specimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimated No of unscreened infants</td>
<td>246 959</td>
</tr>
<tr>
<td>Total No of unscreened infants known to have cystic fibrosis</td>
<td>66 (3/741)</td>
</tr>
<tr>
<td>Not at risk</td>
<td>35</td>
</tr>
<tr>
<td>With meconium ileus</td>
<td>19</td>
</tr>
<tr>
<td>With elder sibling with cystic fibrosis</td>
<td>12</td>
</tr>
</tbody>
</table>
trial. As the Birmingham Children's Hospital is in central Birmingham, and most infants born in the West Midlands with meconium ileus are referred there, there is an abnormally high incidence of children with meconium ileus in the unscreened group of patients. This anomaly does not, however, affect the random allocation of children who were not at risk into the 'screened' and 'clinical' groups at the annual assessment.

Permission for the trial was obtained from the ethics committee of each area health authority. A change in attitude to the protocol in one district of the West Midlands led to stopping the screening early in the West Midlands (October 1989), though screening continued in Wales until December 1989. Patients with cystic fibrosis born in the West Midlands between October and December 1989 were included in the unscreened group. We feel that three months out of a five year period is unlikely to have a significant effect on the random allocation of children into screened and unscreened groups.

Immunoreactive trypsin was measured at 5–10 days by radioimmunoassay using the Behring kit (Hoechst Pharmaceuticals). Subjects with a positive immunoreactive trypsin result (over 900 ng/ml) were retested at 6 to 8 weeks. As immunoreactive trypsin in infants with cystic fibrosis falls with time, the upper limit of normal for the second test was taken as 600 ng/ml and if this was exceeded the child was referred by the general practitioner to the local paediatrician for sweat testing by pilocarpine iontophoresis. No follow up was arranged for infants with only a single positive immunoreactive trypsin value, or for those with two positive results followed by a normal sweat test. Routine treatment included chest physiotherapy, antibiotics according to an agreed protocol, pancreatic enzymes according to clinical need, and vitamin supplementation.

FOLLOW UP OF PATIENTS
Children were assessed on entry to the trial, and various groups were identified based on mode of presentation.

Yearly comparisons were made between infants identified after positive immunoreactive trypsin screening and those diagnosed clinically (the latter group includes those with a false negative immunoreactive trypsin result who were later found to have cystic fibrosis). Infants with meconium ileus and siblings of known patients with cystic fibrosis were considered to be 'at risk' of cystic fibrosis and their results have been excluded from the yearly comparisons.

Each child was reviewed annually by one of us. Detailed information was obtained about the child's health during the previous year including admissions to hospital for illnesses that could be related to cystic fibrosis. A full clinical examination and chest radiograph were done, and height, weight, and skinfold thickness were measured. A blood sample was obtained for various indices: haematological (full blood count, clotting picture, ferritin and folate concentrations); biochemical (plasma electrolyte concentrations, liver function tests, and concentrations of fat soluble vitamins, cholesterol, fatty acids, trace elements, uric acid, and immunoreactive trypsin); immunological (concentrations of immunoglobulins); and for virus titres.

Between annual assessments children were followed up by their local paediatricians.

STATISTICAL ANALYSIS
The distribution of many of the variables was skewed, and consequently comparison of the data is by the non-parametric Mann-Whitney U test.

Results
DETECTION OF INFANTS WITH CYSTIC FIBROSIS
Between January 1985 and December 1989, 227 183 specimens collected in Wales and the West Midlands were routinely screened, and 65 infants with cystic fibrosis were detected after positive screening, of whom 58 were considered not to be 'at risk' (table 1). In addition, 13 specimens from infants subsequently proved to have cystic fibrosis were negative by immunoreactive trypsin screening. Thus there is a total of 78 infants known to have cystic fibrosis in this group giving an incidence of 1/2912. During the same period within the same area an estimated 246 959 specimens were not screened and 66 infants with cystic fibrosis were detected, although only 35 were not 'at risk' (table 2). The

---

![Graph](http://adc.bmj.com)
difference between the total numbers of patients with cystic fibrosis in each group (78 and 66) was not significant ($\chi^2=2.27, df=1, 0.2>p<0.1$), but there was a significant difference between the numbers of infants with cystic fibrosis not 'at risk' (58 and 35) ($\chi^2=7.78, df=1, p<0.01$).

**ASSESSMENT AT ENTRY**

Information at entry into the trial is available on all patients. Infants presenting with meconium ileus and siblings of patients known to have cystic fibrosis have been excluded. Nine children with false negative screening results are included in the group that was diagnosed clinically.

The mean (SD) age at diagnosis of the screened patients (9.1 (3.1) weeks) was significantly lower than that of those clinically diagnosed (50.7 (60.5) weeks) ($p<0.001$, figure).

Symptoms at diagnosis are shown in table 3. Less than one third of the screened group was asymptomatic at the time of diagnosis, while the others had symptoms referable to the respiratory or gastrointestinal systems, or both. Three quarters of the group diagnosed clinically had both respiratory and gastrointestinal symptoms at the time of diagnosis.

Information about hospital admissions with symptoms attributable to cystic fibrosis before the time of diagnosis was available in most cases. In the screened group, 11 of 55 patients had had one such admission, and in only one case was the diagnosis of cystic fibrosis being considered before notification of the positive screening test result. Twenty six of 43 children clinically diagnosed had had at least one such admission.

**ANNUAL ASSESSMENT**

The number of children assessed in each of the first four years of life is shown in table 4. Clinical comparisons were made between infants detected by screening who had no risk factors for cystic fibrosis and children who were diagnosed clinically.

There were no significant differences in weight and height SD scores between the two groups at any age, though there was a tendency for the scores to improve in both groups from the ages of 1–3 years (table 5). Shwachman scores (score for overall well being; points deducted for adverse features; Table 3) Symptoms in infants not considered to be at risk of cystic fibrosis but detected by screening compared with those detected clinically. Figures are expressed as numbers (%) of infants detected by screening

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Infants detected by screening (n=58)</th>
<th>Infants detected clinically (n=64)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory symptoms only</td>
<td>10 (17)</td>
<td>4 (9)</td>
</tr>
<tr>
<td>Gastrointestinal symptoms only</td>
<td>9 (16)</td>
<td>7 (16)</td>
</tr>
<tr>
<td>Respiratory and gastrointestinal symptoms</td>
<td>17 (29)</td>
<td>33 (55)</td>
</tr>
<tr>
<td>Failure to thrive only</td>
<td>6 (10)</td>
<td>0</td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>16 (28)</td>
<td>0</td>
</tr>
</tbody>
</table>

maximum score 100)\(^15\) and Chrispin-Norman scores (chest radiography only; points allocated for adverse features to a total of 38)\(^16\) were similar at the ages of 1 to 4 years. The mean Shwachman scores were between 85 and 90 in both groups and the mean Chrispin-Norman scores between 4 and 7 at all ages.

There were no significant differences between the groups in the results of any of the laboratory tests.

During the first year of life only, the mean (SD) number of hospital admissions (screened 21 (6), clinical 14 (6)) and length of time spent in hospital with illness associated with cystic fibrosis (screened 19.2 (47) days, clinical 27.2 (7.7) days) were significantly greater in the group diagnosed clinically ($p<0.01$). Admissions for diagnosis and initiation of treatment have been excluded from these figures.

**DEATHS**

There have been four deaths so far, all in the group diagnosed clinically. One infant who had presented with meconium ileus and had a positive sweat test, died at the age of 10 weeks of sudden infant death syndrome. Another child with a chest infection who had been confirmed to have cystic fibrosis by two positive sweat tests died at the age of 11 weeks. A third infant with extensive chest infection and a positive sweat test also died at the age of 11 weeks, despite ventilation. A fourth child, who had been treated for asthma, died suddenly at the age of 22 months; at necropsy cardiomyopathy and features of cystic fibrosis were found. No sweat test had been done though it transpired later that this child had had two first cousins with cystic fibrosis. A retrospective immunoreactive trypsin analysis of the neonatal blood sample of the third and fourth patients showed positive results in both cases.

**Discussion**

This large screening study carried out in Wales and the West Midlands over a five year period has shown that neonatal screening for cystic fibrosis could be integrated into the existing national screening programme. Values for specificity and reliability of the immunoreactive trypsin test were similar to those found previously.

The incidence of cystic fibrosis in the screened
population (1/2912) was slightly lower than previously reported, but this figure may have been affected by the exclusion of children born in the West Midlands who had meconium ileus. When the incidence is calculated for Welsh children alone (where this anomaly does not occur) the figure is 1/2671. It is possible that this incidence will increase if more children with negative immunoreactive trypsin tests are found to have cystic fibrosis.

The false negative incidence in this study, at 12.8%, is higher than in some previous reports, but lower than in another. The incidence would not be reduced by lowering the cut off value for the initial immunoreactive trypsin test. In our opinion the immunoreactive trypsin test is not as specific as previously reported and it is important to stress the need for sweat testing where cystic fibrosis is suspected clinically.

The incidence of false positive results in the study is similar to that found by others. The period between the initial positive immunoreactive trypsin test and the result of the sweat test is distressing to families and it is essential to keep this time to a minimum. A survey of some of the families who took part in this study showed that most parents supported screening, whether their child had been screened or clinically diagnosed. All families experienced some change in their feelings for their child after learning the diagnosis, however, and 'several families emphasised the importance of minimal delay between the initial mention of the possibility of cystic fibrosis on immunoreactive trypsin testing and the confirmation (or otherwise) of the diagnosis'.

The identification of the cystic fibrosis gene and major deletion (δ F508) found in about 70% of cystic fibrosis chromosomes of northern European origin could permit rapid diagnosis of about half the patients who develop cystic fibrosis without a previous family history, who are homozygous for this deletion. The obligatory false negative rate of the other half implies that neonatal screening for cystic fibrosis by DNA analysis is not appropriate at present.

During the five years of the study 144 children with cystic fibrosis have entered the trial. Of these, 78 were screened and 66 not screened. When children 'at risk' of cystic fibrosis are excluded there are significantly fewer children in the unscreened group (35 compared with 58 screened). This indicates a possible cohort of children in the unscreened population who have cystic fibrosis who have not yet been diagnosed, and lends support to the theory of Warwick that a substantial number of patients with cystic fibrosis remain undiagnosed, some for years, and some even at necropy.

Analysis of the 'not at risk' groups (screened and clinically diagnosed) permits a comparison of early and late diagnoses and an assessment of the effects of screening. A significant difference is found for age at diagnosis (figure). The SD is wide for the clinical group with 27% over the age of 1 year, the oldest being 4-5 years, which is similar to results reported previously for unscreened patients. Most children who are detected by screening had symptoms attributable to cystic fibrosis at the time of diagnosis and several had already been admitted to hospital. Cystic fibrosis was not considered in some of the clinically diagnosed group until they had had more than one admission to hospital; this has also been reported by Willkening et al. Although the screened patients were diagnosed and treated earlier, we were unable to show any clinical differences between the two groups of patients at the ages of 1 to 4 years. Previous studies have shown differences among older children and it is possible the patient groups will diverge later. The present tests may be too insensitive to detect any differences that are present. Our patients are too young to do lung function tests; when this is possible these tests may allow finer discrimination of when screening is performed between those who were screened and those who were diagnosed clinically.

We did find that the screened children had significantly fewer admissions to, and spent less time in, hospital in the first year of life for problems related to cystic fibrosis, even when admissions for diagnosis and initiation of treatment were excluded. This supports previous findings of reduced morbidity in the early years of life of children with cystic fibrosis who were detected by screening. It may introduce an element of cost effectiveness into screening for cystic fibrosis, but to assess this accurately it would be necessary to know the cost of treatment for patients whose lives were extended by early identification and treatment, if this proved to be the case.

All four deaths occurred in unscreened patients. While this illustrates that infants with cystic fibrosis are vulnerable at a young age, it does not allow any deductions to be made about the effect of screening, as three of the infants died at about the mean time of the recognition of cystic fibrosis by our screening programme—that is, at 2-3 months.

Whatever the effect of earlier diagnosis on the clinical state of children with cystic fibrosis there is little doubt that genetic counselling should be made available to unaffected families as soon as possible, to enable them to make considered decisions on their future family plans.

Although the screening programme ended in December 1989 we plan to follow up the identified cohorts of patients for many years. This should provide the answer to the question of whether early diagnosis and treatment are beneficial to children with cystic fibrosis.

We thank the Directors of the Regional Neonatal Screening Units (Dr RA Carter, West Midlands, and Dr D Bradley, Wales); Dr S Chapman, for reviewing radiographs from the West Midlands, and Professor JA Dodge for helpful discussions. We are grateful to our paediatric colleagues in Wales and the West Midlands for assistance and collaboration. The survey was funded by the Cystic Fibrosis Research Trust, which also supported Dr Chatfield, Dr Owen, Dr Williams, and Dr Alfaham.

2 Crossley JR, Smith PA, Edgar BW, Glueckman PD, Elliott...
Neonatal screening for cystic fibrosis in Wales and the West Midlands


